Vivek Subbiah, MD, is Chief of Early-Phase Drug Development at Sarah Cannon in Nashville, specializing in oncology, Phase 1 trials, and precision medicine. He leads efforts in early-stage cancer drug development and is recognized for his expertise in integrating precision medicine approaches within clinical trials. Dr. Subbiah actively contributes to advancing regulatory discussions on medical AI in healthcare.

‌